Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (9): 1009-1014.
DOI: 10.19803/j.1672-8629.2022.09.16
Previous Articles Next Articles
WEN Dusu1,2, SUN Jianjun3, WANG Yi3,*
Received:
2021-02-04
Online:
2022-09-15
Published:
2022-09-16
CLC Number:
WEN Dusu, SUN Jianjun, WANG Yi. Safety and efficacy of participation of pharmacists in warfarin anticoagulation therapy:a Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1009-1014.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2022.09.16
[1] HIRSH J, FUSTER V, ANSELL J, et al.American heart association/American college of cardiology foundation guide to warfarin therapy[J]. Journal of the American College of Cardiology, 2003, 41(9): 1633-1652. [2] AGENO W, GALLUS AS, WITTKOWSKY A, et al.Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2): e44S-e88S. [3] LINKINS LA, CHOI PT, DOUKETIS JD.Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis[J]. Ann Intern Med, 2003, 139(11): 893-900. [4] KEARON C, AKL EA, COMEROTA AJ, et al.Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2): e419S-e496S. [5] ANSELL J, HIRSH J, Dalen J,et al.Managing oral anticoagulant therapy[J]. Chest, 2001, 119(1): 22s-38s. [6] KONSTANTINIDES SV, MEYER G, Becattini C, et al.2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)[J]. The European Respiratory Journal, 2019, 54(3): 1-68. [7] JANUARY CT, WANN LS, CALKINS H, et al.2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2): e125-e151. [8] NISHIMURA RA, OTTO CM, BONOW RO, et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2017, 135(25): e1159-e1195. [9] CHIQUETTE E, AMATO MG, BUSSEY HI.Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs[J]. Arch Intern Med, 1998, 158(15): 1641-1647. [10] CHAMBERLAIN MA, SAGESER NA, RUIZ D.Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic[J]. J Am Board Fam Prac, 2001, 14(1): 16-21. [11] ZHOU S, SHENG XY, XIANG Q, et al.Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis[J]. Journal of Clinical Pharmacy and Therapeutics, 2016, 41(6): 602-611. [12] HOU K, YANG H, YE Z, et al.Effectiveness of pharmacist-led anticoagulation management on clinical outcomes: A systematic review and meta-analysis[J]. J pharm pharm sci, 2017, 20(1): 378-396. [13] KOSE E, AN T, KIKKAWA A.Assessment of oral anticoagulation control at pharmacist-managed clinics: A retrospective cohort study[J]. Die Pharmazie, 2018, 73(6): 356-360. [14] DU LP, LI Y, LI LL, et al.The impact of clinical pharmacy services on the quality of warfarin anticoagulation therapy management[J]. Chinese Pharmaceutical Journal, 2019, 54(9): 749-752. [15] MANZOOR BS, BAUMAN J, SHAPIRO NL, et al.Outcomes of systematic anticoagulation management in pharmacist and nurse specialized clinics[J]. Journal of the American College of Clinical Pharmacy, 2018, 1: 68-73. [16] YOSHII A, PLAUT DA, MCGRAW KA, et al.Analysis of the reporting of search strategies in Cochrane systematic reviews[J]. J Med Libr Assoc,2009, 97(1): 21-29. [17] STROUP DF, BERLIN JA, MORTON SC, et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting[J]. JAMA,2000, 283(15): 2008-2012. [18] HIGGINS JP, THOMPSON SG, DEEKS JJ, et al.Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-560. [19] AHMED NO, OSMAN B, ABDELHAI YM, et al.Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan[J] . Int J Clin Pharm, 2017, 39(4): 769-773. [20] MIFSUD EM, WIRTH F, CAMILLERI L, et al.Pharmacist-led medicine use review in community pharmacy for patients on warfarin[J]. Int J Clin Pharm, 2019, 41(3): 741-750. [21] KATARUKA A, RENNER E, BARNES GD.Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management[J]. Hosp pract, 2018, 46(1): 16-21. [22] MCKENZIE JA, WILSON-CLARKE C, PROUT J, et al.Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica[J]. Pharm Pract (Granada), 2018, 16(4): 1214. [23] GRAY JA, LUGO RA, PATEL VN, et al.First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment[J]. J Thromb Thrombolysis, 2019, 48(4): 690-693. [24] JONES AE, KING JB, KIM K, et al.The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring[J]. J Thromb Thrombolysis, 2020, 50(3): 739-745. [25] ASHJIAN E, KURTZ B, RENNER E, et al.Evaluation of a pharmacist-led outpatient direct oral anticoagulant service[J]. Am J Health Syst Pharm, 2017, 74(7): 483-489. [26] FALAMIC S, LUCIJANIC M, HADZIABDIC MO, et al.Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial[J]. Int J Clin Pharm, 2018, 40(5): 1078-1085. [27] BUNGARD TJ, RITCHIE B, GARG S, et al.Sustained impact of anticoagulant control achieved in an anticoagulation management service after transfer of management to the primary care physician[J]. Pharmacotherapy, 2012, 32(2): 112-119. [28] LALONDE L, MARTINEAU J, BLAIS N, et al.Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial[J]. Am Heart J, 2008, 156(1): 148-154. [29] VERRET L, COUTURIER J, ROZON A, et al.Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial[J]. Pharmacotherapy, 2012, 32(10): 871-879. [30] JACKSON SL, PETERSON GM, VIAL JH, et al.Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation[J]. J Intern Med, 2004, 256(2): 137-144. [31] SCHILLIG J, KAATZ S, HUDSON M, et al.Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service[J]. J Hosp Med, 2011, 6(6): 322-328. [32] CHAN FW, WONG RS, LAU WH, et al.Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial[J]. Br J Clin Pharmacol, 2006, 62(5): 601-609. [33] WILSON SJ, WELLS PS, KOVACS MJ, et al.Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial[J]. CMAJ, 2003, 169(4): 293-298. [34] LAKSHMI R, JAMES E, KIRTHIVASAN R.Study on impact of clinical pharmacist’s interventions in the optimal use of oral anticoagulants in stroke patients[J]. Indian J Pharm Sci, 2013, 75(1): 53-59. [35] FALAMIC S, LUCIJANIC M, ORTNER HM, et al.Pharmacists’ influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients[J]. Int J Clin Pharm, 2019, 41(5): 1166-1173. [36] AN T, KOSE E, KIKKAWA A, et al.Hospital pharmacist intervention improves the quality indicator of warfarin control: A retrospective cohort study[J]. J Med Invest, 2017, 64(3): 266-271. [37] AIREE A, GUIRGUIS AB, MOHAMMAD RA.Clinical outcomes and pharmacists’acceptance of a community hospital’s anticoagulation management service utilizing decentralized clinical staff pharmacists[J]. Ann Pharmacother, 2009, 43(4): 621-628. [38] ELEWA H, JALALI F, KHUDAIR N, et al.Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar[J]. J Eval Clin Pract, 2016, 22(3): 433-438. [39] SARGENT R, BROCKLEBANK C, TAM TH, ET AL.Advantages of a warfarin protocol for long-term care pharmacists: a retrospective cohort study[J]. Can Geriatr J, 2016, 19(2): 40-49. [40] THANIMALAI S, SHAFIE AA, HASSALI MA, et al.Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital[J]. Int J Clin Pharm, 2013, 35(5): 736-743. [41] WITT DM, SADLER MA, SHANAHAN RL, et al.Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy[J]. Chest, 2005, 127(5): 1515-1522. [42] YOUNG S, BISHOP L, TWELLS L, et al.Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic[J]. BMC Fam Pract, 2011, 12: 88. [43] MARTIN CY, HERMANN SA, COULDRY RJ.Impact of pharmacist-managed warfarin on patient outcomes in an academic medical center[J]. Am J Health Syst Pharm, 2015, 72(11): S31. [44] HALL D, BUCHANAN J, HELMS B, ET AL.Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care[J]. Pharmacotherapy, 2011, 31(7): 686-694. [45] SAOKAEW S, PERMSUWAN U, CHAIYAKUNAPRUK N, et al.Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis[J]. J Thrombo Haemost, 2010, 8(11): 2418-2427. [46] TAJER C, CERESETTO J, BOTTARO FJ, et al.Assessment of the quality of chronic anticoagulation control with time in therapeutic range in atrial fibrillation patients treated with vitamin K antagonists by hemostasis specialists: the TERRA registry: tiempo en rango en la republica Argentina[J]. Clin Appl Thromb hemost, 2017, 23(5): 445-453. [47] VESTERGAARD AS, SKJOTH F, LARSEN TB, et al.The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis[J]. PloS one, 2017, 12(11): e0188482. [48] SOLVIK UO, LOKKEBO ES, KRISTOFFERSEN AH, et al.Self-management of warfarin therapy[J]. Tidsskr Nor Laegeforen, 2015, 135(9): 849-853. [49] MA ZY, CHENG G, WANG P, et al.Clinical model for predicting warfarin sensitivity[J]. Sci Rep, 2019, 9(1): 12856. [50] LIMDI NA, WADELIUS M, CAVALLARI L, et al.Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups[J]. Blood, 2010, 115(18): 3827-3834. [51] JOHNSON JA, CAVALLARI LH.Warfarin pharmacogenetics[J]. Trends Cardiovasc Med, 2015, 25(1): 33-41. [52] JOHNSON JA, CAUDLE KE, GONG L, et al.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update[J]. Clin Pharmacol Ther, 2017, 102(3): 397-404. [53] GUPTA V, KOGUT SJ, Thompson S.Evaluation of differences in percentage of international normalized ratios in range between pharmacist-led and physician-led anticoagulation management services[J]. J Pharm Pract, 2015, 28(3): 249-255. |
[1] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[2] | JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106. |
[3] | ZHANG Lei, LYU Jian, XIE Yanming. Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806. |
[4] | CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816. |
[5] | LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824. |
[6] | CHENG Fengjingming, LYU Jian, XIE Yanming. Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543. |
[7] | SU Xinxin, LYU Jian, XIE Yanming. Efficacy and safety of Toutongning capsules in the treatment of chronic headache: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 433-440. |
[8] | SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285. |
[9] | YANG Caihua, YANG Longna, LI Xiaobo. Two cases of fetal malformation after exposure to low dose warfarin sodium tablets in early pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1286-1289. |
[10] | ZHANG Wenwen, NIE Xiting, XU Huiru, RAN Ye, TIAN Chenglin, YU Shengyuan. One case of extremely abnormal coagulation caused by warfarin combined with compound paracetamol and amantadine hydrochloride tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1290-1292. |
[11] | LIU Tiantian, CAO Junling, ZHANG Yanli, GONG Ying, GU Yuanyuan. Research progress in enhancing anticoagulant effects of warfarin and the mechanism by traditional Chinese medicine for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 117-120. |
[12] | ZHAO Xiaoxiao, LIU Fumei, XI Junyu, SHI Buwen, XIE Yanming, WANG Lianxin. Systematic evaluation and Meta-analysis of Danhuang Quyu capsules in the treatment of chronic pelvic inflammatory disease [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1002-1008. |
[13] | MU Sicong, WANG Zhuo, LU Junyang, JI Liwei, LIU Xin. Effects of pioglitazone on plasma adiponectin in patients with type 2 diabetes mellitus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1015-1018. |
[14] | WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin. Pareto chart analysis of 705 problematic prescriptions in neurology [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903. |
[15] | YUAN Xiaolong, WAN Qihua, TAO Donghong, QI Hao, WANG Aixia. Pharmaceutical care of a severely poisoned patient with methotrexate tablets [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 924-928. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||